Similar articles

• Neonatal adiposity following maternal treatment of gestational diabetes with glyburide compared with insulin.

  Lain KY, Garabedian MJ, Daftary A, Jeyabalan A. Lain KY, et al. Am J Obstet Gynecol. 2009 May;200(5):501.e1-6. doi: 10.1016/j.ajog.2009.02.038. Am J Obstet Gynecol. 2009. PMID: 19375570 Clinical Trial.
• Perinatal outcomes and the use of oral hypoglycemic agents.

  Bertini AM, Silva JC, Taborda W, Becker F, Lemos Bebber FR, Zucco Viesi JM, Aquim G, Engel Ribeiro T. Bertini AM, et al. J Perinat Med. 2005;33(6):519-23. doi: 10.1515/JPM.2005.092. J Perinat Med. 2005. PMID: 16318615 Clinical Trial.
• Oral hypoglycemic agents in pregnancy.

  Refuerzo JS. Refuerzo JS. Obstet Gynecol Clin North Am. 2011 Jun;38(2):227-34, ix. doi: 10.1016/j.ogc.2011.02.013. Obstet Gynecol Clin North Am. 2011. PMID: 21575798
• Management of gestational diabetes: pharmacologic treatment options and glycemic control.

  Langer O. Langer O. Endocrinol Metab Clin North Am. 2006 Mar;35(1):53-78, vi. doi: 10.1016/j.ecl.2005.09.007. Endocrinol Metab Clin North Am. 2006. PMID: 16310642 Review. No abstract available.
• Using oral agents to manage gestational diabetes: what have we learned?

  Buschur E, Brown F, Wyckoff J. Buschur E, et al. Curr Diab Rep. 2015 Feb;15(2):570. doi: 10.1007/s11892-014-0570-5. Curr Diab Rep. 2015. PMID: 25620403 Review.